Compare Gilead Sciences, Inc. (GILD) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Charles Schwab Corporation Common Stock — how do they compare? Gilead Sciences, Inc. trades at $132.92 (market cap $163.51B), while Charles Schwab Corporation Common Stock trades at $102.96 (market cap $178.77B). The key difference: Gilead Sciences, Inc. and Charles Schwab Corporation Common Stock are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | SCHW | |
|---|---|---|
Market Cap | $163.51B | $178.77B |
Sector | Health | Financials |
52-Week High | $155.80 | $107.21 |
52-Week Low | $108.22 | $85.35 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Charles Schwab (SCHW) trades at $101.10, down 1.25% today, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential near-term overbought conditions. Recent financial performance demonstrates robust revenue growth to $23.92 billion in 2025 and net income margin expansion to 37.99%, supported by strong trading activity and asset management fees.
The outlook remains positive with analyst consensus pointing to 25.9% upside potential to $123.71. Key catalysts include continued earnings growth and strong retail trading activity, while risks involve interest rate sensitivity and market volatility. With 58% of analysts maintaining buy ratings and improving cash flow trends, SCHW presents a compelling investment case for growth-oriented investors despite current valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
